Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
PTC Therapeutics, Inc. PTCT
$54.84
+$0.04 (0.07%)
На 18:00, 12 мая 2023
-13.84%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
4067876300.00000000
-
week52high
57.42
-
week52low
25.01
-
Revenue
698801000
-
P/E TTM
-7
-
Beta
0.42318300
-
EPS
-8.17000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 10:59
Описание компании
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Raymond James | Outperform | Outperform | 11 авг 2022 г. |
| RBC Capital | Sector Perform | Sector Perform | 23 июн 2022 г. |
| JP Morgan | Overweight | Overweight | 23 февр 2022 г. |
| Barclays | Equal-Weight | Equal-Weight | 23 февр 2022 г. |
| RBC Capital | Sector Perform | Sector Perform | 29 окт 2021 г. |
| Jefferies | Buy | 12 сент 2022 г. | |
| Morgan Stanley | Equal-Weight | 09 сент 2022 г. | |
| Citigroup | Buy | 01 сент 2022 г. | |
| RBC Capital | Sector Perform | Sector Perform | 17 окт 2022 г. |
| RBC Capital | Sector Perform | Sector Perform | 28 окт 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 28 окт 2022 г. |
| Credit Suisse | Neutral | Neutral | 28 окт 2022 г. |
| Credit Suisse | Neutral | Neutral | 10 янв 2023 г. |
| Goldman Sachs | Sell | 14 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Peltz Stuart Walter | D | 54903 | 301 | 31 янв 2023 г. |
| Peltz Stuart Walter | D | 166962 | 2320 | 31 янв 2023 г. |
| Utter Christine Marie | D | 38059 | 325 | 31 янв 2023 г. |
| Almstead Neil Gregory | D | 3259 | 28 | 31 янв 2023 г. |
| Almstead Neil Gregory | D | 63949 | 630 | 31 янв 2023 г. |
| Boulding Mark Elliott | D | 75378 | 812 | 31 янв 2023 г. |
| Hill Emily Luisa | D | 46288 | 575 | 31 янв 2023 г. |
| Pauwels Eric | D | 65537 | 375 | 31 янв 2023 г. |
| Almstead Neil Gregory | D | 3287 | 44 | 24 янв 2023 г. |
| Hill Emily Luisa | D | 46863 | 223 | 24 янв 2023 г. |
Новостная лента
PTC Therapeutics, Inc. (PTCT) Q1 2023 Earnings Call Transcript
Seeking Alpha
28 апр 2023 г. в 01:20
PTC Therapeutics, Inc. (PTCT) Q1 2023 Earnings Call Transcript.
PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
27 апр 2023 г. в 19:01
PTC Therapeutics (PTCT) came out with a quarterly loss of $1.88 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to loss of $1.78 per share a year ago.
PTC Therapeutics (PTCT) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research
27 апр 2023 г. в 13:42
PTC Therapeutics (PTCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PTC Therapeutics Announces CEO Stuart Peltz Is Resigning
Pulse2
25 мар 2023 г. в 09:55
Stuart Peltz, Ph.D., founding Chief Executive Officer (CEO) of PTC Therapeutics announced that he is stepping down after 25 years.
PTC Therapeutics, Inc. (PTCT) Q4 2022 Earnings Call Transcript
Seeking Alpha
21 февр 2023 г. в 22:35
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q4 2022 Earnings Conference Call February 21, 2023 4:30 PM ET Company Participants Kylie O'Keefe - Chief Commercial Officer Stuart Peltz - Chief Executive Officer Matthew Klein - Chief Operating Officer Eric Pauwels - Chief Business Officer Emily Hill - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Brian Abrahams - RBC Joseph Thome - Cowen David Lebowitz - Citi Kelly Shi - Jefferies Tazeen Ahmad - Bank of America Gena Wang - Barclays Mike Riad - Morgan Stanley Paul Choi - Goldman Sachs Danielle Brill - Raymond James Operator Good day, and welcome to the PTC Therapeutics Fourth Quarter 2022 Corporate Update and Financial Results Call. At this time, all participants are in a listen-only mode.